Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody rituximab in patients aged 61 to 80 years with aggressive non-Hodgkin's lymphoma

Trial Profile

Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody rituximab in patients aged 61 to 80 years with aggressive non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RICOVER-60
  • Most Recent Events

    • 12 Dec 2017 Interim results compare patient outcome with the old (fixed) and the new PET-adapted (flexible) treatment strategy, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Aug 2017 Results of pooled data of clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within two prospective clinical trials (RICOVER-60 and R-MegaCHOEP) of the German high-grade non-Hodgkin's lymphoma study group were, published in the Journal of Clinical Oncology.
    • 06 Jun 2017 Results of pooled data of anti-infective prophylaxis with aciclovir and cotrimoxazole from two prospective DSHNHL trials (OPTIMAL > 60 and RICOVER-60) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top